These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 37118061)
1. Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4). Goldfarb DS; Lieske JC; Groothoff J; Schalk G; Russell K; Yu S; Vrhnjak B Urolithiasis; 2023 Apr; 51(1):80. PubMed ID: 37118061 [TBL] [Abstract][Full Text] [Related]
2. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Baum MA; Langman C; Cochat P; Lieske JC; Moochhala SH; Hamamoto S; Satoh H; Mourani C; Ariceta G; Torres A; Wolley M; Belostotsky V; Forbes TA; Groothoff J; Hayes W; Tönshoff B; Takayama T; Rosskamp R; Russell K; Zhou J; Amrite A; Hoppe B; Kidney Int; 2023 Jan; 103(1):207-217. PubMed ID: 36007597 [TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Hoppe B; Koch A; Cochat P; Garrelfs SF; Baum MA; Groothoff JW; Lipkin G; Coenen M; Schalk G; Amrite A; McDougall D; Barrios K; Langman CB Kidney Int; 2022 Mar; 101(3):626-634. PubMed ID: 34481803 [TBL] [Abstract][Full Text] [Related]
4. Nedosiran Safety and Efficacy in PH1: Interim Analysis of PHYOX3. Groothoff J; Sellier-Leclerc AL; Deesker L; Bacchetta J; Schalk G; Tönshoff B; Lipkin G; Lemoine S; Bowman T; Zhou J; Hoppe B Kidney Int Rep; 2024 May; 9(5):1387-1396. PubMed ID: 38707801 [TBL] [Abstract][Full Text] [Related]
5. Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1. Zhang S; Amrite A; Tan B; Jamsen K; Pradhan S; Choy S; Plotkin H Br J Clin Pharmacol; 2024 Aug; ():. PubMed ID: 39113219 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Hoppe B; Groothoff JW; Hulton SA; Cochat P; Niaudet P; Kemper MJ; Deschênes G; Unwin R; Milliner D Nephrol Dial Transplant; 2011 Nov; 26(11):3609-15. PubMed ID: 21460356 [TBL] [Abstract][Full Text] [Related]
8. Safety, Pharmacokinetics, and Exposure-Response Modeling of Nedosiran in Participants With Severe Chronic Kidney Disease. Amrite A; Fuentes E; Marbury TC; Zhang S Clin Pharmacol Drug Dev; 2023 Dec; 12(12):1164-1177. PubMed ID: 37605486 [TBL] [Abstract][Full Text] [Related]
9. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial. Frishberg Y; Deschênes G; Groothoff JW; Hulton SA; Magen D; Harambat J; Van't Hoff WG; Lorch U; Milliner DS; Lieske JC; Haslett P; Garg PP; Vaishnaw AK; Talamudupula S; Lu J; Habtemariam BA; Erbe DV; McGregor TL; Cochat P; Clin J Am Soc Nephrol; 2021 Jul; 16(7):1025-1036. PubMed ID: 33985991 [TBL] [Abstract][Full Text] [Related]
10. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Ariceta G; Barrios K; Brown BD; Hoppe B; Rosskamp R; Langman CB Kidney Int Rep; 2021 Apr; 6(4):1088-1098. PubMed ID: 33912759 [TBL] [Abstract][Full Text] [Related]
17. Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1. Sas DJ; Mara K; Mehta RA; Seide BM; Banks CJ; Danese DS; McGregor TL; Lieske JC; Milliner DS Pediatr Nephrol; 2024 Jan; 39(1):141-148. PubMed ID: 37458799 [TBL] [Abstract][Full Text] [Related]
18. New therapeutics for primary hyperoxaluria type 1. Dejban P; Lieske JC Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):344-350. PubMed ID: 35266883 [TBL] [Abstract][Full Text] [Related]
19. Etiology, urine metabolic risk factors, and urine oxalate patterns in patients with significant hyperoxaluria and recurrent nephrolithiasis. Moore JP; Mauler DJ; Narang GL; Stern KL; Humphreys MR; Keddis MT Int Urol Nephrol; 2022 Nov; 54(11):2819-2825. PubMed ID: 35917078 [TBL] [Abstract][Full Text] [Related]